Perrigo Company PLC

Perrigo Company PLC(PRGO)股票分析

$16.630

+0.151 (+0.91%)收盤時

Loading chart…
最高
16.680
開盤
16.540
成交量加權均價
16.52
成交量
2.44M
市值
—
最低
16.260
成交金額
40.31M
企業價值/稅息折舊攤銷前利潤(TTM)
9.24

Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief.

AI 分析 of Perrigo Company PLC (PRGO)

買進

Perrigo Company PLC is a good buy right now due to its current price of $15.06 being below the analyst target price of $15.25, suggesting room for growth. Additionally, the stock has shown a 5-day change of +5.61%, indicating positive momentum. However, investors should be cautious of the company's recent financial challenges, including a net income loss of $398.6 million in Q1 2026, which poses a risk to profitability.

分析師評級(18)

上檔空間 +22.25%
持有
6 買進
11 持有
1 賣出
目前: 16.63
最低
18.00
平均
20.33
最高
23.00

JPMorgan

2026-02-27

目標價

$15

中性

Canaccord

2026-02-27

目標價

$17

買進

JPMorgan

2025-12-15

目標價

$18

中性

Canaccord

2025-11-06

目標價

$20

買進

JPMorgan

2025-11-06

目標價

$20

中性

估值指標

Perrigo Company PLC(PRGO)目前預期本益比為 5.97,5 年平均預期本益比為 10.60。

預期本益比

低估
5 年均值 P/E
10.60
目前P/E
5.97
高估
14.57
低估
6.63

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
9.36
目前EV/EBITDA
9.24
高估
13.30
低估
5.43

預期股價營收比

低估
5 年均值 P/S
0.84
目前P/S
0.56
高估
1.10
低估
0.59

Alphio AI 對 PRGO 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%PRGO

$33.09

情境價格

基

基準

基準 · 50%PRGO

$30.61

情境價格

悲

悲觀

悲觀 · 25%PRGO

$29.15

情境價格

持有 PRGO 的大戶

B

BW Gestao de Investimentos Ltda.

+ 持有PRGO

+2.45%

3個月報酬率

S

Sound Income Strategies, LLC

+ 持有PRGO

-3.77%

3個月報酬率

事件時間軸

2026-10-09 (ET)

16:30:00

Rumor of Perrigo Takeover Highlighted in Blog

2026-08-05 (ET)

07:00:00

Company Reports Q2 Revenue of $1.02B, Exceeding Expectations

07:00:00

Company Lowers FY26 Revenue Outlook by 1.5%-5.5%

2026-06-30 (ET)

17:00:00

Perrigo Appoints Salman Amin and Omer Gajial as Independent Directors

2026-06-10 (ET)

13:40:00

Perrigo rumor highlighted in Betaville blog

資訊

PRGO 常見問題 —— 由 Alphio AI 解答

Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Perrigo Company PLC is a good buy right now due to its current price of $15.06 being below the analyst target price of $15.25, suggesting room for growth. Additionally, the stock has shown a 5-day change of +5.61%, indicating positive momentum. However, investors should be cautious of the company's recent financial challenges, including a net income loss of $398.6 million in Q1 2026, which poses a risk to profitability.

18 analysts cover PRGO: 6 rate it Buy, 11 Hold and 1 Sell. The average price target is 20.33.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易